NRX Pharmaceuticals Income Statement (2024-2025) | NRXP

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter) -0.23M0.24M0.98M
Cost of Revenue (Quarter) 0.10M0.41M
Gross Profit (Quarter) 0.14M0.57M
Operating items
Depreciation & Amortization - Total (Quarter) -0.99M2.00M-3.99M
Research & Development (Quarter) 1.75M2.80M0.61M1.04M0.99M1.43M0.56M
Selling, General & Administrative (Quarter) 4.25M4.25M2.41M2.60M2.74M2.81M4.57M
Restructuring Costs (Quarter) -1.20M-0.09M0.03M
Other Operating Expenses (Quarter) -2.03M-8.43M-5.66M0.78M
Operating Expenses (Quarter) 6.00M7.05M3.02M2.43M3.73M4.27M5.61M
Operating Income (Quarter) -6.00M-7.05M-3.02M-2.43M-3.85M-3.73M-4.02M-4.62M
EBIT (Quarter) -6.00M-7.05M-3.02M-2.43M-3.85M-3.73M-4.02M-4.62M
Non-operating items
Interest & Investment Income (Quarter) 0.03M0.01M0.01M0.00M0.00M0.00M0.00M0.00M
Other Non Operating Income (Quarter) -0.01M
Non Operating Income (Quarter) -0.53M-0.85M1.40M-6.65M-13.85M-1.87M4.98M
Net income details
EBT (Quarter) -6.20M-7.04M-3.02M-2.43M-3.84M-3.73M-4.02M-5.29M
Profit After Tax (Quarter) -6.53M-7.90M-1.62M-9.08M-5.51M-17.58M-5.89M0.36M
Income from Continuing Operations (Quarter) -6.20M-7.04M-3.02M-2.43M-3.84M-3.73M-4.02M-5.29M
Consolidated Net Income (Quarter) -6.20M-7.04M-3.02M-2.43M-3.84M-3.73M-4.02M-5.29M
Income towards Parent Company (Quarter) -6.20M-7.04M-3.02M-2.43M-3.84M-3.73M-4.02M-5.29M
Net Income towards Common Stockholders (Quarter) -6.20M-7.04M-3.02M-2.43M-3.84M-3.73M-4.02M-5.29M
Additional items
EPS (Basic) (Quarter) -0.74-0.75-0.15-0.77-0.40-0.98-0.270.20
EPS (Weighted Average and Diluted) (Quarter) -0.74
Shares Outstanding (Weighted Average) (Quarter) 4.03M4.07M10.97M10.64M9.56M17.18M18.88M9.36M
Shares Outstanding (Diluted Average) (Quarter) 8.85M
EBITDA (Quarter) -6.00M-7.90M-1.63M-9.07M-3.85M-3.73M-5.89M-8.61M
Interest Expenses (Quarter) 0.23M0.67M